Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Meta Platforms Inc (META) Price & Performance

BridgeBio Pharma IncTrade
Meta Platforms IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Meta Platforms Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Meta Platforms Inc trades at $600.22 (market cap $1.52T). The key difference: Meta Platforms Inc is far larger — about 91.5× BridgeBio Pharma Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOMETA
Market Cap
$16.61B$1.52T
Sector
HealthMedia
52-Week High
$90.17$790.00
52-Week Low
$47.29$525.72
Enterprise Value
$18.16B$1.54T
Volume
24,093,972
Dividend Yield
0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Meta Platforms Inc

META trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed. Technical indicators show bearish momentum with RSI at 96.23 suggesting overbought conditions. The company launched Muse Spark AI model and faces ongoing legal challenges regarding youth addiction lawsuits.

Outlook remains positive with analyst consensus price target of $761.95 (28% upside) and 79% buy ratings. Key risks include regulatory lawsuits, aggressive AI capex spending ($102B in 2025), and competitive pressures. Revenue growth continues at 22% year-over-year to $201B, supporting long-term investment thesis despite near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Meta Platforms Inc

Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.

Read more on META